Hexima Limited announced that it has filed a design patent covering important consumer oriented designs of the proposed commercial packaging for pezadeftide, its proprietary product in development to treat onychomycosis. Hexima will hold an investor webinar on 2 September 2021 (AEST) to discuss the importance of the design covered in the patent. The commercial package is intended to enhance the experience of patients using pezadeftide to treat their onychomycosis. In the webinar, the company will also introduce the design of a mobile application Hexima intends to implement as a companion application to facilitate patients connecting with their doctor, monitoring treatment progress, up-loading photographs, and refilling prescriptions. Two aspects of consumer attractiveness are built in with company product. First, pezadeftide appears to work very rapidly delivering a patient-friendly and convenient short course of therapy. Onychomycosis is a common fungal nail infection in the nail plate and nail bed. Prevalence of onychomycosis has been estimated at between 10% (Japan) and 13.8% (USA).1 Onychomycosis is an infectious disease and is difficult to treat with significant healthcare burden. It causes pain in approximately 50% of patients and in the US results in close to four doctor's visits annually for treatment.2 Onychomycosis impacts a patient's quality of life with 51% unable to wear the shoes they would prefer and 66% distressed by the appearance of their nail. It is important to treat onychomycosis as the fungi in the nail and can be a source of secondary infection in other areas of the body or infect family members and spread to the environment. Onychomycosis is the most common nail disorder accounting for 50% of all nail diseases. It is particularly prevalent in older, diabetic and immune compromised populations.2 The global market for treatments for onychomycosis was approximately USD 3.7 billion in 2018. Approved prescription therapies for onychomycosis comprise either oral or topical medications. Oral medications are associated with adverse effects such as nausea, taste disturbance, and flatulence. They can also severely impact liver function and so often require liver function monitoring. The clinical and commercial success of topical medications has been constrained by an inability of anti-fungal agents to effectively penetrate the human nail and the lack of sufficient anti-fungal activity when in contact with the target pathogen.